Shares of Allergy Therapeutics plc (LON:AGY – Get Free Report) hit a new 52-week high during trading on Monday . The stock traded as high as GBX 12 and last traded at GBX 12, with a volume of 195754 shares trading hands. The stock had previously closed at GBX 11.50.
Allergy Therapeutics Trading Up 4.3%
The company has a quick ratio of 1.48, a current ratio of 1.63 and a debt-to-equity ratio of 835.48. The stock has a fifty day simple moving average of GBX 9.25 and a 200 day simple moving average of GBX 8.45. The firm has a market capitalization of £736.97 million, a P/E ratio of -16.67, a PEG ratio of -30.70 and a beta of 1.40.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
See Also
- Five stocks we like better than Allergy Therapeutics
- Wall Street Stock picker Names #1 Stock of 2026
- Do not delete, read immediately
- They Laughed at $30. They Won’t Laugh at $70.
- How Long Will $1M Last in Retirement?
- “$6.6 Trillion Of Customer Bank Deposits At Risk”
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
